IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Summary

To find the highest tolerable dose of IACS-6274 that can be given alone, in combination with bevacizumab and paclitaxel, or in combination with capivasertib to patients who have solid tumors. The safety and tolerability of the study drug(s) will also be studied.

Conditions

• Advanced Endometrial Carcinoma
• Advanced Head and Neck Squamous Cell Carcinoma
• Advanced Malignant Solid Neoplasm
• Advanced Melanoma
• Advanced Ovarian Clear Cell Adenocarcinoma
• Chondrosarcoma
• Clinical Stage III Cutaneous Melanoma AJCC v8
• Clinical Stage IV Cutaneous Melanoma AJCC v8
• Pathologic Stage III Cutaneous Melanoma AJCC v8
• Pathologic Stage IIIA Cutaneous Melanoma AJCC v8
• Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
• Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
• Pathologic Stage IIID Cutaneous Melanoma AJCC v8
• Pathologic Stage IV Cutaneous Melanoma AJCC v8
• Recurrent Ovarian High Grade Serous Adenocarcinoma
• Refractory Endometrial Carcinoma
• Refractory Head and Neck Squamous Cell Carcinoma
• Refractory Melanoma
• Refractory Ovarian Clear Cell Adenocarcinoma
• Refractory Ovarian High Grade Serous Adenocarcinoma
• Stage III Ovarian Cancer AJCC v8
• Stage III Uterine Corpus Cancer AJCC v8
• Stage IIIA Ovarian Cancer AJCC v8
• Stage IIIA Uterine Corpus Cancer AJCC v8
• Stage IIIA1 Ovarian Cancer AJCC v8
• Stage IIIA2 Ovarian Cancer AJCC v8
• Stage IIIB Ovarian Cancer AJCC v8
• Stage IIIB Uterine Corpus Cancer AJCC v8
• Stage IIIC Ovarian Cancer AJCC v8
• Stage IIIC Uterine Corpus Cancer AJCC v8
• Stage IIIC1 Uterine Corpus Cancer AJCC v8
• Stage IIIC2 Uterine Corpus Cancer AJCC v8
• Stage IV Ovarian Cancer AJCC v8
• Stage IV Uterine Corpus Cancer AJCC v8
• Stage IVA Ovarian Cancer AJCC v8
• Stage IVA Uterine Corpus Cancer AJCC v8
• Stage IVB Ovarian Cancer AJCC v8
• Stage IVB Uterine Corpus Cancer AJCC v8

Interventions

BIOLOGICAL

Bevacizumab

Given IV

DRUG

Glutaminase-1 Inhibitor IACS-6274

Given by PO

DRUG

Paclitaxel

Given by IV (vein)

DRUG

Capivasertib

Given by PO

Sponsors & Collaborators

• M.D. Anderson Cancer Center

  lead OTHER

Principal Investigators

• Timothy A Yap, MD · M.D. Anderson Cancer Center

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-09-09

Primary Completion

2026-05-29

Completion

2026-05-29

FDA Drug

Yes

Countries

• United States

Study Locations